A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
To determine whether HMG-CoA reductase inhibitor simvastatin prevents or ameliorates
subarachnoid hemorrhage-induced delayed vasospasm and its ischemic consequences.